Read by QxMD icon Read

Axitinib AND Gastrointestinal Stromal Tumors

Yi Qian, Lei Yu, Xue-Hui Zhang, Qing-Yun Yuan-Zi, Ping Zhao, Lu-Ning Sun, Yong-Qing Wang
Platelet-derived Growth Factor Receptor (PDGFR) is one of the families of Receptor Tyrosine Kinases (RTKs), which have attracted increasing attention as a potential target of antitumor therapy in cancer. PDGFR family members consist of PDGFR-α, PDGFR-β, CSF-1R, KIT and FLT3. Tyrosine Kinase Inhibitors (TKIs) are a kind of small molecule inhibitors targeting RTKs. TKIs prevent and block vital pathways by targeting signaling molecules which are necessary for cell survival. At present, about 11 kinds of TKIs targeting PDGFR family members have been approved for the treatment of diseases like chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), etc...
June 28, 2018: Current Drug Metabolism
Vinod Patel, Chris Sproat, Jerry Kwok, Nikki Tanna
Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw...
November 2017: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
B McLellan, F Ciardiello, M E Lacouture, S Segaert, E Van Cutsem
BACKGROUND: Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in colorectal cancer and gastrointestinal stromal tumors. In clinical trials, regorafenib showed a consistent and predictable adverse-event profile, with hand-foot skin reaction (HFSR) among the most clinically significant toxicities. This review summarizes the clinical characteristics of regorafenib-related HFSR and provides practical advice on HFSR management to enable health care professionals to recognize, pre-empt, and effectively manage the symptoms, thereby allowing patients to remain on active therapy for as long as possible...
October 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
V Grünwald, M Rickmann
Recent years have seen dramatic changes in the biological understanding and treatment of solid tumors. Based on the tumor biology, targeting agents have been developed which directly affect the underlying genetic or immunological changes found in specific tumor entities. Significant increases in survival have delivered the functional proof of the concept of targeted and immunological tumor therapy. The management and adherence of the patient as well as optimized cooperation with clinicians are decisive for the results of therapy and disease control...
October 2014: Der Internist
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"